Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis

Award Number: R44HL172475
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis - ABSTRACT: Fibrotic disorders represent a major health problem in the U.S, with a rising incidence (particularly among the elderly). Idiopathic pulmonary fibrosis (IPF) is a relentless and fatal fibrotic disease, characterized by progressive scar tissue formation in the lungs, resulting respiratory failure. There are two FDA-approved treatments for IPF, which slow but do not stop the decline in lung function, and only have a modest survival benefit. Improved therapies for IPF and other fibrotic diseases are needed to improve patient quality of life and outcomes. We were the first to identify Nox4 (an oxidant generating enzyme) as a critical mediator of lung fibrosis. Nox4 is now considered to be a core pathway that mediates fibrosis in various organs (lungs, liver, skin, kidney, blood vessels, skeletal muscle, and heart). We have also demonstrated that Nox4 becomes dysfunctional in aging, where its sustained upregulation promotes age-associated persistent/progressive fibrosis – These findings may help to explain why fibrotic disorders develop are more prevalent among the elderly. Although Nox4 is among the most promising drug targets for fibrotic disease, selective Nox4 inhibitors have yet to be successfully developed – until now. This direct to Phase II SBIR application is a collaboration between biotech startup company Fibronox LLC and Emory University. We have pioneered the development of first-in-class selective Nox4 inhibitor drug candidates; 10 patents filed. Our Nox4 inhibitors have passed a rigorous screening cascade, including nM potency in vitro for inhibiting TGFb-induced pro-fibrotic effects and reversing IPF myofibroblast phenotypes. Importantly, therapeutic treatment with Nox4 inhibitor candidates in vivo led to protection from the development of fibrosis and promoted the resolution of age-associated established fibrosis. Further, inhaled delivery of Nox4 inhibitors demonstrated efficacy at a dose ~7-fold lower than orally administered and 4-fold increased drug exposure in the lung. The goal of the proposed studies is to perform side-by-side evaluation of our top 3 most promising candidates via inhaled delivery in order to identify one development candidate for IND-enabling studies and subsequent clinical development. Aim 1 will rigorously validate top candidates for selectivity and mode of action. Aim 2 will de-risk top candidates through advanced screening, including the use of human precision cut lung slices, single-cell RNAseq, and highly a innovative bioinformatic approach to evaluate Nox4 inhibitors vs. standard of care. Aim 3 will evaluate specificity and potential for adverse effects. Aim 4 will determine the therapeutic index and maximum tolerated dose. To date, no therapeutics have been shown to reverse age- associated established fibrosis, which may represent the holy grail for therapeutic strategies to more effectively treat IPF. We hypothesize that therapeutic strategies targeting age-associated pathologic mechanisms (ex. age- dependent sustained Nox4/ROS levels) offer the greatest potential for developing successful IPF treatments.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	FIBRONOX, L.L.C.	1001 E 17TH ST	TUCSON	AZ	85719	PIMA	USA	Lung Diseases Research	000	2	3/30/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,091,039 )
2025	2025	FIBRONOX, L.L.C.	1001 E 17TH ST	TUCSON	AZ	85719	PIMA	USA	Lung Diseases Research	000	2	8/25/2025	NON-COMPETING CONTINUATION	$1,091,039
														Subtotal = $1,091,039

Issue Date FY: 2024 ( Subtotal = $954,681 )
2024	2024	FIBRONOX, L.L.C.	1001 E 17TH ST	TUCSON	AZ	85719	PIMA	USA	Lung Diseases Research	000	1	5/31/2024	NEW	$954,681
2024	2024	FIBRONOX, L.L.C.	1001 E 17TH ST	TUCSON	AZ	85719	PIMA	USA	Lung Diseases Research	001	1	8/7/2024	NEW	$0
														Subtotal = $954,681

Grand Total All Awards = $2,045,720

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis

Award Number: R44HL172475

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer